XOMA Royalty Corporation (NASDAQ:XOMA) Receives Consensus Rating of “Hold” from Brokerages

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) have received an average rating of “Hold” from the six ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $61.60.

A number of research firms have recently weighed in on XOMA. Benchmark reaffirmed a “buy” rating on shares of XOMA Royalty in a report on Friday, December 12th. UBS Group set a $76.00 price objective on XOMA Royalty in a research note on Tuesday, December 9th. TD Cowen raised shares of XOMA Royalty to a “hold” rating in a research note on Friday, February 13th. HC Wainwright restated a “buy” rating and issued a $97.00 price target on shares of XOMA Royalty in a research report on Friday. Finally, Leerink Partners reiterated an “outperform” rating on shares of XOMA Royalty in a research report on Tuesday, February 24th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State of Alaska Department of Revenue acquired a new position in XOMA Royalty in the 4th quarter valued at approximately $27,000. Russell Investments Group Ltd. grew its holdings in shares of XOMA Royalty by 3,436.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 756 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,523 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 543 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of XOMA Royalty during the second quarter worth $116,000. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Royalty Stock Down 0.2%

Shares of NASDAQ:XOMA opened at $28.71 on Friday. The stock has a market capitalization of $341.94 million, a price-to-earnings ratio of 19.66 and a beta of 0.86. XOMA Royalty has a 1-year low of $18.35 and a 1-year high of $39.92. The company’s fifty day moving average is $26.09 and its two-hundred day moving average is $30.46. The company has a debt-to-equity ratio of 1.15, a quick ratio of 3.91 and a current ratio of 3.37.

XOMA Royalty (NASDAQ:XOMA) last issued its earnings results on Wednesday, March 18th. The biotechnology company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.16. The company had revenue of $13.76 million during the quarter, compared to the consensus estimate of $11.13 million. XOMA Royalty had a return on equity of 10.32% and a net margin of 45.75%. Equities analysts anticipate that XOMA Royalty will post -1.41 EPS for the current year.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.